Skip to content

Study Details

Testing a Study Drug (Lutikizumab) for Adults and Adolescents with Abbvie Hidradenitis Suppurativa

(IRB#: IRB_00178446)

The purpose of this study is to assess the safety and efficacy of lutikizumab compared with placebo (fake drug) for the treatment of signs and symptoms of moderate to severe hidradenitis suppurativa (HS) in adult and adolescents subjects (16 years of age or older were permitted). People in the study will be randomly chosen to be treated with Lutikizumab or a placebo for the first 16 weeks. The placebo looks like the drug but does not have the medication. The drug and placebo are taken as an injection under the skin. At Week 16, patients will be randomily assigned to receive lutikizumab every week or every other week. Being in the study requires multiple ways of participation such as writing in a journal at home and attending in person at a study clinic for about 1 year. Medical tests will be done during the study to track the health of participants.

I AM INTERESTED

  • All genders
  • Over 7 years old
  • Volunteers with special conditions
  •   In Person
  • Paid

Who can participate?

 Gender: All genders

  Age: Over 7 years old

  Volunteers: Volunteers with special conditions

   Location: In Person

Inclusion Criteria

  • Diagnosis of Hidradenitis Suppurativa at least 6 months prior to participation
  • Hidradenitis Suppurativa must be present on at least 2 parts of the body
  • Willing and able to fully participate in all required study activities
  • Use specific birth control approved by the study

Exclusion Criteria

  • History of active skin disease other than Hidradenitis Suppurativa
  • Treated with another study drug 30 days before receiving first dose of the study drug
  • Receive a live vaccine, such as the flu (mist) vaccine, within 28 days prior to the first dose of the study drug
  • History of drug or alcohol abuse 6 months prior to participation
  • Pregnant or breastfeeding

Will I be paid for my time?

Yes

For more information contact:

Angela Contreras

angela.contreras@hsc.utah.edu

  801-213-0374

IRB#: IRB_00178446

PI: Jamie Rhoads

Department: DERMATOLOGY

Approval Date: 2024-11-13 07:00:00

Specialties: Dermatology

Last Updated: 6/8/23